MergerApr 27, 2026, 04:34 PM
GYRE to Acquire Cullgen for $300M; Shareholder Vote on Stock Issuance
AI Summary
Gyre Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders on June 10, 2026, to vote on several key proposals. These include the election of two Class II directors, an advisory vote on executive compensation, and the ratification of Grant Thornton as the independent auditor. Most notably, shareholders will vote on the issuance of common stock related to the conversion of Series B Convertible Preferred Stock, which is part of the previously announced all-stock acquisition of Cullgen Inc. for approximately $300 million. Upon the merger's closing, Cullgen's CEO, Ying Luo, Ph.D., will become GYRE's CEO and President.
Key Highlights
- GYRE to acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million.
- Shareholders to vote on common stock issuance for Series B Preferred Stock conversion related to Cullgen merger.
- Annual Meeting of Stockholders scheduled for June 10, 2026, to elect two Class II directors.
- Shareholders to vote on non-binding advisory basis for executive officer compensation.
- Ratification of Grant Thornton as independent auditor for 2026.
- Upon merger close, Ying Luo, Cullgen CEO, to become GYRE CEO and President.
- Audit Fees for 2025 were $721,505; Tax Fees were $13,425.
Price Impact
More from GYRE